News
SPRC
4.520
-4.24%
-0.200
SciSparc Files June 30, 2026 Interim Results on Form 6-K
TipRanks · 4d ago
Weekly Report: what happened at SPRC last week (0921-0925)?
Weekly Report · 09/28 09:58
Clearmind Reports U.S. Patent Applications For Drug Combinations In Mental Health
NASDAQ · 09/26 16:35
Psychedelic: Optimi completes psilocybin production for Phase 2 trial
TipRanks · 09/24 14:30
SciSparc’s NeuroThera Expands U.S. Patent Portfolio for Psychedelic-PEA Therapies with Clearmind
TipRanks · 09/24 13:29
SciSparc expands U.S. IP portfolio in collaboration with Clearmind Medicine
TipRanks · 09/23 12:46
Weekly Report: what happened at SPRC last week (0914-0918)?
Weekly Report · 09/21 09:58
Weekly Report: what happened at SPRC last week (0907-0911)?
Weekly Report · 09/14 10:02
Weekly Report: what happened at SPRC last week (0831-0904)?
Weekly Report · 09/07 09:57
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 09/02 21:06
SciSparc’s NeuroThera Advances Enrollment in SCI-210 Autism Trial
TipRanks · 09/02 20:27
SciSparc Subsidiary Pursues FDA Orphan Drug Status For Tourette Syndrome Drug
NASDAQ · 09/02 13:02
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation Covering SCI-110
Benzinga · 09/02 12:18
SciSparc's NeuroThera Enrolls First Six Patients In SCI-210 Autism Trial
NASDAQ · 09/01 08:06
Closing Bell Movers: Duolingo up 4% after Evercore upgrade
TipRanks · 08/31 23:35
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 08/31 21:06
SciSparc subsidiary provides update on SCI-210 trial enrollment
TipRanks · 08/31 20:10
SciSparc Says NeuroThera Labs Advances Participant Enrollment For Clinical Trial Assessing SCI-210 Treatment For Symptoms Associated With Autism Spectrum Disorder
Benzinga · 08/31 20:04
Weekly Report: what happened at SPRC last week (0824-0828)?
Weekly Report · 08/31 10:02
Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment
TipRanks · 08/27 16:10
More
Webull provides a variety of real-time SPRC stock news. You can receive the latest news about Scisparc through multiple platforms. This information may help you make smarter investment decisions.
About SPRC
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.